文献速递类风湿关节炎

类风湿关节炎患者妊娠结局与普通人群比较:法国全国前瞻性匹配研究

Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study.
PubMed 文献 · RMD Open · 2026-07-08

该法国前瞻性多中心队列纳入2015至2021年100例类风湿关节炎(RA)妊娠,与359例匹配普通人群对照比较。RA组早产(OR 2.08,95%CI 1.04–4.09)及小于胎龄儿(SGA)风险显著升高,妊娠期泼尼松等效剂量≥10 mg/天与早产相关(aOR 4.91,95%CI 1.30–10.59)。

要点

  • RA妊娠早产风险约为普通人群2倍,SGA风险亦显著升高
  • 妊娠期糖皮质激素≥10 mg/天与早产风险升高相关
  • 未产与SGA风险升高相关,母体年龄与早产风险升高相关

核心结论

  • 在该以三级中心随访为主的当代队列中,RA妊娠仍存在早产和SGA风险增加。
  • 妊娠期全身糖皮质激素≥10 mg/天是早产的独立危险因素,但不能完全排除疾病活动度的贡献。

研究设计与样本

  • 法国前瞻性多中心队列,纳入2015至2021年90例RA孕妇共100次妊娠。
  • 对照为2016和2021年法国围产期调查中匹配的359例普通人群孕妇,采用单变量分析比较妊娠结局,多变量logistic回归识别相关因素。

主要发现

  • RA孕妇平均年龄33.7±5.0岁,57.6%为未产。
  • 妊娠期46%使用糖皮质激素,39%使用生物改善病情抗风湿药。
  • 与359例普通人群对照相比,RA妊娠早产OR 2.08(95%CI 1.04–4.09)。
  • SGA<第10百分位OR 2.11(95%CI 1.12–3.94),SGA<第3百分位OR 3.21(95%CI 1.13–9.44)。

关键数值与推荐

  • SGA与未产相关(aOR 4.38,95%CI 1.12–9.78)。
  • 早产与母体年龄相关(aOR 1.14,95%CI 1.01–1.30)。
  • 早产与妊娠期糖皮质激素≥10 mg/天相关(aOR 4.91,95%CI 1.30–10.59)。

临床怎么用

  • 对RA孕妇应加强早产和胎儿生长监测,尤其未产及高龄孕妇。
  • 妊娠期尽量将糖皮质激素维持在<10 mg/天,以降低早产风险。

局限性

  • 样本量较小(100次妊娠),以三级中心随访为主,外推需谨慎。
  • 不能完全排除母体疾病活动度对早产风险的贡献。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of the study was to assess the contemporary frequency of adverse pregnancy outcomes in women with rheumatoid arthritis (RA) and to identify associated factors. METHODS: This French prospective multicentre cohort included pregnant women with RA between 2015 and 2021. Maternal characteristics, disease activity, treatments and pregnancy outcomes were analysed. Outcomes of pregnancies in women with RA were compared in univariable analysis with those of matched general population women from the 2016 and 2021 French perinatal surveys assessing maternal and neonatal health. Multivariable logistic regressions were performed to identify factors associated with adverse outcomes. RESULTS: A total of 100 pregnancies in 90 women with RA were analysed. Mean maternal age was 33.7±5.0 years and 57.6% were nulliparous. During pregnancy, 46% received glucocorticoids and 39% biologic disease-modifying antirheumatic drugs. Compared with the 359 controls from the general population, preterm birth (OR 2.08, 95% CI 1.04 to 4.09) and small for gestational age (SGA) (ORSGA 10th percentile 2.11, 95% CI 1.12 to 3.94; ORSGA 3rd percentile 3.21, 95% CI 1.13 to 9.44) rates were higher in RA pregnancies. SGA was associated with nulliparity (adjusted OR (aOR) 4.38, 95% CI 1.12 to 9.78), whereas preterm birth was associated with maternal age (aOR 1.14, 95% CI 1.01 to 1.30) and exposure to glucocorticoids at doses ≥10 mg/day during pregnancy (aOR 4.91, 95% CI 1.30 to 10.59). CONCLUSION: In this contemporary cohort mostly followed in tertiary care centres, pregnancies in women with RA remained at increased risk of preterm birth and SGA. Exposure to systemic glucocorticoids at doses ≥10 mg/day emerged as a risk factor for preterm birth, although a contribution of maternal disease activity cannot be entirely excluded.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Hamroun S, Martin de Frémont G, Costedoat-Chalumeau N, et al. Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study. RMD Open. 2026. PMID: 42419787. doi:10.1136/rmdopen-2026-006922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。